clinical trials in cancer treatment – Science

Breakthrough Discoveries from MD Anderson: Research Highlights – September 5, 2025

SCIENMAG — Fri, 05 Sep 2025 17:26:21 +0000

The University of Texas MD Anderson Cancer Center continues to spearhead transformative advances in oncological research, with its latest breakthroughs promising to reshape cancer treatment paradigms across multiple tumor types. Combining state-of-the-art clinical trials and cutting-edge molecular technologies, these innovative studies highlight significant progress in treating pancreatic, colorectal, kidney, breast, stomach, and testicular cancers, alongside novel insights into biomarkers predictive of metastasis in oral cancer.

A notable clinical trial led by Drs. Chad Tang and Pavlos Msaouel has demonstrated the potential of metastasis-directed targeted radiation therapy to delay systemic treatment initiation in patients with oligometastatic clear cell renal cell carcinoma (ccRCC). This Phase II trial enrolled 121 patients, achieving impressive two- and three-year survival rates of 94% and 87%, respectively. Patients were able to avoid systemic therapies — such as immunotherapy and targeted agents, which often pose considerable side effects — for a median of 34 months. Integral to this approach was the use of a novel circulating tumor DNA (ctDNA) assay, which detected minimal residual disease, enabling clinicians to stratify patients based on likelihood of treatment failure. Those without detectable ctDNA remained off systemic therapy twice as long as their counterparts, underscoring the test’s promise as a noninvasive biomarker and patient selection tool.

In parallel, immunotherapeutic innovation continues with the cancer vaccine ELI-002, co-led by Dr. Shubham Pant, targeting KRAS-mutated pancreatic and colorectal cancers. The vaccine is designed to provoke robust T-cell responses against tumor-specific neoantigens localized within lymph nodes, a critical site for anti-tumor immunity induction. Long-term data from the AMPLIFY-201 trial reveal that 68% of patients mounted strong T-cell reactivity correlated with prolonged relapse-free survival; notably, median recurrence-free survival had not been reached even at 24 months post-treatment. These promising results have catalyzed a Phase II trial incorporating an expanded vaccine formulation (ELI-002 7P) aimed at additional KRAS mutations, a key driver mutation historically challenging to target.

Challenges in treatment-resistant colorectal cancer have been tackled through a novel triple combination strategy targeting microsatellite stable (MSS) BRAF V600E-mutant metastatic colorectal cancer, as investigated by Dr. Van Morris and colleagues. The BRAF V600E mutation confers aggressive phenotypes with dismal prognoses and limited therapeutic options. While FDA-approved targeted agents such as encorafenib and cetuximab exist, their efficacy is often time-limited. The addition of the PD-1 immune checkpoint inhibitor nivolumab in a Phase I/II trial yielded a 50% overall response rate and a median progression-free survival exceeding seven months. Liquid biopsy-based RNA analyses further elucidated distinct molecular signatures differentiating responders, bolstering personalized treatment stratification and seeding a nationwide Phase II trial (SWOG S2107).

At the forefront of understanding tumor heterogeneity, Dr. Nicholas Navin’s team has unveiled a groundbreaking single-cell sequencing platform, wellDR-seq, enabling the simultaneous capture of DNA and RNA profiles within individual breast cancer cells. This technology permits unprecedented molecular dissection of chromosomal alterations and transcriptional regulation in estrogen receptor-positive breast tumors. Profiling 33,646 cells, the researchers mapped the clonal evolution and gene expression dynamics underpinning tumor initiation and progression. These insights not only illuminate pathways driving invasive and aggressive phenotypes but also hold potential for broader application across diverse diseases where cellular heterogeneity is relevant.

Another stride in precision medicine emerged from Yuan-Hung Lo’s team, who leveraged CRISPR gene editing within human-derived stomach organoids to elucidate gene-drug interactions that modulate cisplatin chemotherapy sensitivity. The high-throughput CRISPR screening identified an unexpected link between cellular fucosylation — a sugar modification process — and cisplatin cytotoxicity, highlighting the TAF6L gene as a central orchestrator of cellular recovery mechanisms. These findings underscore the power of organoid CRISPR platforms to uncover novel therapeutic targets and predictive biomarkers that may refine chemotherapeutic regimens.

On the frontier of targeted therapeutics, a collaboration involving Drs. Kathleen McAndrews, Anirban Maitra, Raghu Kalluri, and Timothy Heffernan has characterized BI-2493, a first-in-class pan-KRAS inhibitor demonstrating robust antitumor efficacy in preclinical models. Unlike existing KRAS inhibitors, BI-2493 targets a broad spectrum of KRAS mutants, overcoming the limitation of allele specificity. In pancreatic cancer models, BI-2493 suppressed tumor proliferation and activated immune microenvironment remodeling by increasing the infiltration of immune effector cells while diminishing immunosuppressive myeloid populations. These results reveal mechanistic synergy between direct oncogenic signaling blockade and enhanced immunotherapy responsiveness, paving the way for combinatorial approaches targeting KRAS-driven malignancies.

Addressing a critical unmet need in germ-cell tumors, Dr. Yago Nieto led a Phase II trial evaluating high-dose chemotherapy combined with bevacizumab, specifically targeting DNA damage repair pathways in multiply relapsed or refractory testicular cancers. Despite high initial cure rates with cisplatin-based chemotherapy, a subset of patients face poor prognoses upon relapse. The trial’s five-year relapse-free and overall survival rates exceeded expectations at 54% and 55.5%, confirming the value of intensifying DNA repair-targeted approaches. Although bevacizumab addition did not enhance outcomes, validation through a larger prospective cohort reinforces the scientific rationale for pursuing DNA repair modulation in this population.

Innovations are also improving surgical oncology through enhanced detection of pre-cancerous lesions. Dr. Charles Manning’s laboratory developed V-1520, a near-infrared fluorescent tracer targeting a protein biomarker enriched in tumor-associated macrophages within pancreatic cancer microenvironments. This probe allows intraoperative visualization of high-risk pre-malignant lesions, facilitating complete resection and potentially reducing recurrence. Importantly, V-1520 selectively binds to inflammatory signatures linked to malignancy but not benign pancreatitis, demonstrating specificity that could be translated to other tumor types, augmenting precision surgical interventions.

In the realm of molecular diagnostics, Dr. Koichi Takahashi and colleagues have identified predictive biomarkers for oral cancer metastasis by mapping the tumor microenvironment with high spatial resolution. They discovered that elevated presence of myofibroblastic cancer-associated fibroblasts (myCAFs) at the invasive tumor front correlates with enhanced lymph node metastasis and poorer prognosis. These myCAFs appear to act as “accomplices,” supporting cancer cell dissemination. A 23-gene spatial molecular signature derived from this study enables early prediction of metastasis potential, highlighting the complex interplay between tumor cells and their microenvironment and opening avenues for targeted stromal therapies.

These multiple breakthroughs cement MD Anderson’s role at the vanguard of cancer research, bridging molecular insights with translational impact. The ongoing integration of genomic technologies, immunotherapy, targeted agents, and innovative clinical trial designs epitomizes a new era in oncology, offering hope for durable remissions and improved survival across diverse cancer types.

Subject of Research: Cancer research spanning pancreatic, colorectal, kidney, breast, stomach, testicular, and oral cancers with focus on targeted therapies, immunotherapy vaccines, molecular diagnostics, and tumor microenvironment.

Article Title: MD Anderson’s 2025 Research Highlights: Breakthroughs in Cancer Therapeutics and Molecular Insights

News Publication Date: September 5, 2025

References:
See associated journal publications in The Lancet Oncology, Nature Medicine, Cancer Cell, Cell, Nature Communications, Science Translational Medicine, Clinical Cancer Research, and PLOS Genetics linked in the web references.

Keywords:
Cancer research, Pancreatic cancer, Stomach cancer, Colorectal cancer, Oral cancer, Breast cancer, Cancer genomics, Genome sequencing, Biomarkers, Cancer immunotherapy, Chemotherapy, Radiation therapy

Five Breakthroughs in Radiotherapy for Anal and Rectal Cancer Treatment

SCIENMAG — Sat, 03 May 2025 21:13:23 +0000

In a groundbreaking series of clinical trials unveiled at ESTRO 2025, advances in radiotherapy have ushered in a new era for the treatment of rectal and anal cancers, offering hope for improved patient outcomes while minimizing the often devastating side effects of surgery. Traditionally, rectal cancer management has depended heavily on invasive surgical procedures that, although effective at tumor removal, come with significant drawbacks including impacts on sexual function, bowel continence, and overall quality of life. However, emerging research now points toward the feasibility and efficacy of organ-preserving approaches centered around novel radiotherapy techniques, often in conjunction with chemotherapy and immunotherapy, fundamentally reshaping the treatment landscape.

Rectal cancer, a malignancy developing in the distal segment of the large intestine just upstream of the anus, ranks among Europe’s most prevalent cancers, with an annual incidence surpassing 125,000 cases. Standard care typically involves radical surgery following neoadjuvant therapies aimed at tumor downsizing, yet this approach is marred by lasting functional impairments and lifestyle alterations for survivors. The oncology community has therefore asserted the need for less invasive modalities that preserve normal anatomy and function without sacrificing oncological control. This aspiration has galvanized a wave of clinical trials exploring the promise of intensified and personalized radiotherapy, conditions under which some patients achieve complete tumor eradication, eliminating the surgical necessity.

In parallel, anal cancer, characterized by malignancy in the lowest portion of the gastrointestinal tract, presents a distinct clinical challenge. Although relatively rare (about 14,000 cases annually in Europe), it is notably more sensitive to radiotherapy. Historical trials have demonstrated that combined chemoradiation can preclude the need for extensive surgery and permanent colostomies. Despite this advantage, traditional regimens are often accompanied by high incidences of acute and delayed toxicities, underscoring the urgency to refine treatment protocols that improve tolerance while maintaining high efficacy.

Among the most compelling findings at ESTRO 2025 is the ACT4 PLATO trial, a randomized phase II study conducted across numerous UK centers, which evaluated reduced-dose, short-course intensity-modulated radiotherapy (IMRT) for early-stage anal cancer. The results reveal that a shorter treatment course—delivered over 4.5 weeks with a lower radiation dose—achieved tumor control rates comparable to the standard 5.5-week regimen but with significantly fewer side effects. This advancement is a critical milestone that not only lessens the patient burden in terms of time and toxicity but also aligns with health systems’ goals for resource optimization.

Complementing this, the STAR-TREC trial has rigorously assessed organ preservation in rectal cancer by comparing radiotherapy alone to chemoradiotherapy in early to intermediate-risk patients. The study’s findings are impressive: 80% of patients undergoing concurrent chemoradiotherapy and 61% of those receiving radiotherapy alone avoided surgery at the one-year mark. These outcomes suggest that radiotherapy-based strategies can conservatively treat tumors while sparing patients the morbidity of invasive procedures, marking a shift toward personalized treatment paradigms that prioritize both survival and functional integrity.

Another striking development is highlighted in the PRIME-RT trial from the UK, where the integration of immunotherapy with short-course radiotherapy has demonstrated a dramatic increase in complete response rates—67% of evaluable patients experienced full tumor eradication after just five outpatient radiotherapy sessions combined with immunotherapy. By harnessing the immunomodulatory effects of radiation to potentiate immune checkpoint blockade, this strategy exemplifies how multimodal treatment regimens can synergistically enhance outcomes and offers a blueprint for future therapeutic combinations.

China’s STELLAR II study further reinforces the potential of integrating immunotherapy with radiotherapy and chemotherapy. Patients receiving this triple combination exhibited a 45.5% rate of complete tumor disappearance, notably surpassing the 25% seen with standard treatment approaches. This finding highlights the ability of immunotherapy to amplify the radiosensitizing effects of chemotherapy and radiotherapy, paving the way for treatments that not only eradicate cancer more effectively but also facilitate organ preservation, thereby preserving patient quality of life.

The phase III STELLAR trial, which enrolled 591 patients with locally advanced rectal cancer, provides long-term evidence favoring short-course radiotherapy followed by chemotherapy over traditional long-course chemoradiotherapy. Impressively, this regimen improved five-year survival rates by 8.4% without compromising anorectal function or quality of life, suggesting a new standard of care that is both more efficient in treatment delivery and more tolerable for patients. Such data may catalyze revisions of clinical guidelines globally.

Collectively, these five transformative studies underscore a paradigm shift in colorectal cancer treatment: radiotherapy is no longer solely an adjunct to surgery but is becoming a cornerstone of curative, organ-preserving care. The careful tailoring of radiotherapy dose, fractionation, and combination with systemic therapies demonstrates impressive potential to maintain oncological efficacy while dramatically reducing adverse effects that have long plagued patients.

Underpinning these advances is the maturation of precision radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), which allows high-precision targeting of tumor tissues while sparing surrounding healthy structures. When paired with systemic agents like chemotherapy drugs and immune checkpoint inhibitors, these approaches harness different mechanisms of tumor control—radiation-induced DNA damage, cell cycle arrest, and immune activation—to achieve synergistic effects not possible with monotherapy.

Experts at ESTRO 2025 emphasize the broader implications of these findings beyond individual patient care. The adoption of shorter, lower-dose radiotherapy regimens could alleviate logistical demands on healthcare providers, speed up treatment timelines, and reduce costs without compromising treatment success. Moreover, improved quality of life outcomes help address survivorship concerns, cementing the relevance of organ preservation strategies in holistic cancer care.

“This is a watershed moment in colorectal oncology,” said one leading researcher. “We are witnessing the convergence of technological innovation, immunological insights, and clinical rigor that collectively enable us to treat cancers more effectively while respecting the patient’s quality of life. Radiotherapy is no longer a blunt instrument but a refined tool that, when expertly applied, can transform outcomes.”

As these data begin influencing global clinical guidelines, a new consensus is emerging that embraces multimodal, personalized, and organ-preserving strategies as the cornerstone of future colorectal cancer care. This shift promises not only improved survival statistics but a fundamental redefinition of what it means to cure cancer—by preserving the patients’ dignity, function, and overall well-being.

The European Society for Radiotherapy and Oncology (ESTRO) continues to spearhead this transformation by fostering international collaboration, education, and research dissemination aimed at universal access to advanced radiotherapy. The ongoing commitment to innovation and patient-centered approaches heralds a hopeful future in the fight against colorectal cancers, combining scientific excellence with compassionate care.

Subject of Research: Advanced radiotherapy strategies for organ preservation and improved survival in rectal and anal cancers

Article Title: Radiotherapy Innovations Redefine Treatment Paradigms for Rectal and Anal Cancer: Organ Preservation and Enhanced Survival Highlight ESTRO 2025 Findings

News Publication Date: 4 May 2025

Web References:

References:

Abstract E25-3665, ACT4 PLATO Trial
Abstract E25-1489, STAR-TREC Trial
Abstract E25-1116, PRIME-RT Trial
Abstract E25-837, STELLAR II Trial
Abstract E25-2250, Phase III STELLAR Trial

Keywords: Radiation therapy, colorectal cancer, organ preservation, rectal cancer, anal cancer, immunotherapy, chemoradiotherapy, intensity-modulated radiotherapy (IMRT), clinical trials, cancer treatment innovation

UCLA Researchers Showcase Breakthroughs in Prostate and Bladder Cancer, AI Applications, and Patient-Centered Care at AUA 2025

SCIENMAG — Mon, 21 Apr 2025 20:22:48 +0000

In a groundbreaking showcase of medical innovation and clinical research, the annual meeting of the American Urological Association (AUA) will spotlight cutting-edge advances emanating from investigators at UCLA’s David Geffen School of Medicine and the UCLA Health Jonsson Comprehensive Cancer Center. This premier event, scheduled from April 26 to 29, 2025, in Las Vegas, will feature more than forty sessions where the latest discoveries and improvements in patient care within urology will take center stage. Central to the UCLA presentations are novel technologies and research findings with the potential to redefine diagnostic precision, surgical planning, and therapeutic strategies in urologic oncology and functional urology.

A significant portion of attention is directed toward the integration of three-dimensional digital modeling in robotic prostatectomy procedures. The pioneering study, spearheaded by Dr. Joseph Shirk alongside resident Dr. Asha Ayub, involved a randomized, single-blinded clinical trial across six distinguished academic institutions over a period from 2019 to 2022. This comprehensive research demonstrated that utilization of 3D models in preoperative planning prompted surgeons to adjust their surgical approach in a third of the cases. Unlike traditional multiparametric MRI, these models offered enhanced visualization of the tumor’s spatial relationships with critical neurovascular structures, thereby enabling refined nerve-sparing techniques. Notably, this augmentation translated into improved oncological clearance with negative surgical margins and superior functional outcomes, including early return of continence and erectile functionality maintained up to 18 months post-surgery.

Parallel to surgical innovations, economic analyses in immunotherapy reflected crucial insights, particularly regarding checkpoint inhibitors for muscle-invasive bladder cancer. Researchers led by Dr. Alexandra Drakaki and clinical instructor Dr. Pratik Kanabur developed a long-term cost-effectiveness model comparing pembrolizumab and nivolumab—two leading immunotherapeutic agents—against surveillance post-cystectomy in high-risk patient populations. Utilizing data from landmark trials such as CheckMate 274 and AMBASSADOR, the model integrated multifaceted inputs including quality-adjusted life years (QALYs), toxicity profiles, and healthcare expenditure. While both agents demonstrated substantial improvements in disease-free survival versus surveillance, pembrolizumab emerged as more cost-effective with a notably lower incremental cost-effectiveness ratio (ICER) at approximately $50,000 per QALY gained. This analysis underscores the necessity of integrating economic considerations alongside efficacy when developing personalized treatment protocols.

Artificial intelligence continues to revolutionize diagnostic interpretation and prognostication within urology. A compelling study from UCLA investigates the application of AI-generated prostate cancer risk mapping to predict seminal vesicle invasion (SVI), a critical determinant in treatment planning. The research employed multimodal preoperative imaging combined with clinical parameters to construct three-dimensional cancer estimation maps. These maps provided superior predictive accuracy compared to expert radiologist assessments on MRI, whose sensitivity was limited by inherent challenges such as suboptimal resolution and reader variability. Remarkably, AI algorithms missed far fewer SVI cases across two distinct patient cohorts, suggesting that machine learning-driven imaging interpretation could significantly enhance preoperative staging and therapeutic targeting.

Monitoring bladder dynamics after spinal cord injury presents complex challenges, particularly due to neurogenic lower urinary tract dysfunction (NLUTD) and its associated risks, such as autonomic dysreflexia (AD). Researchers, led by Dr. Lynn Stothers, introduced a novel wearable optical device that non-invasively tracks bladder volume and pressure fluctuations in real time using near-infrared spectroscopy (NIRS). This wireless system, comprising paired emitter-detector LED arrays embedded in a soft silicone interface, measures changes in light attenuation correlating with urine volume and detrusor muscle oxygenation. Clinical evaluation in 66 spinal cord injured patients revealed distinct optical markers that aligned with detrusor pressure changes, enabling early detection of bladder overdistension. This real-time feedback mechanism holds exceptional promise for personalizing catheterization schedules and mitigating life-threatening AD episodes, which affect approximately one-fifth of the NLUTD cohort.

Another transformative dimension in urological care is the optimization of shared decision-making (SDM) for kidney stone management. UCLA investigators, including Dr. Christopher Saigal and Saam Kazemi, addressed implementation hurdles for an innovative online decision aid designed to facilitate patient-physician collaboration in treatment choices. Over a three-month enrollment period, the study assessed key metrics such as ‘reach’—the proportion of eligible patients invited to use the tool—and ‘fidelity’—the rate of proper decision aid completion by patients. Initial adoption rates fell short of targeted benchmarks, prompting iterative quality improvement interventions grounded in Plan-Do-Study-Act (PDSA) cycles. The research highlights the intricate balance between technological accessibility and clinical engagement required to effectively integrate decision aids into routine practice, ultimately advancing patient-centered care.

Collectively, these multifaceted UCLA-led investigations exemplify a holistic embrace of technological innovation, cost-conscious clinical strategy, and patient empowerment within the urologic field. The convergence of 3D surgical planning, economic modeling of immunotherapies, AI-enhanced imaging diagnostics, wearable physiological monitoring, and digital decision-making tools heralds a new era where multidisciplinary science tangibly improves outcomes and quality of life for patients facing complex urologic diseases. The presentations set for the AUA 2025 meeting promise to catalyze vibrant discussions and foster collaborative initiatives that will propel urology into an increasingly precise, personalized, and proactive discipline.

With the meeting set against the dynamic backdrop of The Venetian Convention & Expo Center in Las Vegas and sessions carefully scheduled across specialized venues such as Marco Polo and Galileo halls, attendees will have the opportunity to engage deeply with UCLA’s clinician-scientists and their transformative work. The integration of real-world clinical trial data, sophisticated analytical modeling, and cutting-edge AI methodologies affirms UCLA’s position at the forefront of urologic innovation, poised to shape national and international standards of care.

In shifting paradigms of prostate cancer surgery, robotic-assisted procedures augmented with digital 3D models underscore the imperative of visualizing tumor architecture and neuroanatomy to reduce collateral damage. Likewise, elucidating nuanced cost-effectiveness dynamics in bladder cancer therapies ensures that life-extending benefits align with sustainable healthcare resource allocation. AI’s burgeoning role in cancer risk mapping not only excels in diagnostic sensitivity but also points toward AI’s potential for streamlining preoperative workflows and enhancing multidisciplinary planning discussions.

Beyond oncology, the wearable bladder monitoring system addresses significant unmet needs in managing neurogenic bladder dysfunction, demonstrating the powerful application of optical physics and biomedical engineering principles to neurological urology. The ongoing development and refinement of shared decision-making frameworks mirror broader healthcare trends emphasizing transparency, patient autonomy, and personalized therapeutics.

In sum, UCLA’s contributions showcased at AUA 2025 embody a watershed moment for urology — where technological sophistication merges with humanistic care to realize better patient experiences and clinical outcomes. As these insights permeate clinical practice and inform future research, they promise to inspire a transformative wave of innovation across the global urology community.

Subject of Research: Innovations in Urologic Oncology and Functional Urology, including 3D surgical modeling, immunotherapy cost-effectiveness, AI-driven cancer diagnostics, wearable bladder monitoring, and shared decision-making in kidney stone care.

Article Title: UCLA Researchers Unveil Breakthroughs in Urology at AUA 2025: From 3D Models to AI Diagnostics and Wearable Technologies

News Publication Date: April 2025

Web References:

Keywords: Urology, Prostate Cancer, Robotic Surgery, 3D Modeling, Bladder Cancer, Checkpoint Inhibitors, AI Diagnostics, Seminal Vesicle Invasion, Neurogenic Bladder, Wearable Optical Device, Shared Decision-Making, Kidney Stones